Literature DB >> 17605963

Brain injury after cardiopulmonary arrest and its assessment with diffusion-weighted magnetic resonance imaging.

Kevin M Barrett1, William D Freeman, Steven M Weindling, Thomas G Brott, Daniel F Broderick, Michael G Heckman, Julia E Crook, Gavin D Divertie, James F Meschia.   

Abstract

OBJECTIVE: To characterize the frequency and pattern of diffusion-weighted imaging (DWI) abnormalities detected as part of brain magnetic resonance imaging (MRI) and their association with short-term neurologic outcomes in patients successfully resuscitated after cardiopulmonary arrest (CPA). PATIENTS AND METHODS: We retrospectively analyzed a case series of patients who experienced CPA between May 1, 2000, and April 29, 2004, at St Luke's Hospital in Jacksonville, Fla. Eligible patients required treatment by the Code Blue team and had 1 DWI study before discharge or death. Two neuroradiologists jointly classified DWI abnormalities by anatomic location. Outcome was measured by Cerebral Performance Category score.
RESULTS: Resuscitation was performed 628 times during the 48-month study period. Of 514 CPA survivors, 18 (3.5%) had MRI studies. The median age was 62 years (interquartile range [IQR], 49-73), and 10 were men. Median code duration was 16 minutes (IQR, 11-19 minutes), and median code-to-scan time was 72 hours (IQR, 28-229 hours). A DWI abnormality was noted in 9 (50%) of 18 patients. Cortical areas (global and regional) were the most common sites of restricted diffusion. Diffusion-weighted imaging abnormalities were present in 7 (70%) of 10 patients with a poor neurologic outcome at discharge.
CONCLUSION: Magnetic resonance imaging is performed rarely after survival of CPA. In this study with limited sample size, a greater proportion of patients with normal DWI findings had a good neurologic outcome at the time of hospital discharge vs those with abnormal findings. Prospective studies of early and serial MRI (with DWI) are needed to confirm this association and to clarify the prognostic usefulness of such studies.

Entities:  

Mesh:

Year:  2007        PMID: 17605963     DOI: 10.4065/82.7.828

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

1.  Temporal and spatial profile of brain diffusion-weighted MRI after cardiac arrest.

Authors:  Michael Mlynash; Dennis M Campbell; Emily M Leproust; Nancy J Fischbein; Roland Bammer; Irina Eyngorn; Amie W Hsia; Michael Moseley; Christine A C Wijman
Journal:  Stroke       Date:  2010-07-01       Impact factor: 7.914

2.  Multi-Center Study of Diffusion-Weighted Imaging in Coma After Cardiac Arrest.

Authors:  K G Hirsch; M Mlynash; I Eyngorn; R Pirsaheli; A Okada; S Komshian; C Chen; S A Mayer; J F Meschia; R A Bernstein; O Wu; D M Greer; C A Wijman; G W Albers
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

3.  Diffusion-weighted magnetic resonance imaging for predicting the clinical outcome of comatose survivors after cardiac arrest: a cohort study.

Authors:  Seung Pill Choi; Kyu Nam Park; Hae Kwan Park; Jee Young Kim; Chun Song Youn; Kook Jin Ahn; Hyeon Woo Yim
Journal:  Crit Care       Date:  2010-02-12       Impact factor: 9.097

4.  Forebrain ischemia triggers GABAergic system degeneration in substantia nigra at chronic stages in rats.

Authors:  B Lin; S Levy; A P Raval; M A Perez-Pinzon; R A Defazio
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-10-14

5.  Imaging for Neuroprognostication After Cardiac Arrest: Systematic Review and Meta-analysis.

Authors:  Neill K J Adhikari; Damon C Scales; Carmen Lopez Soto; Laura Dragoi; Chinthaka C Heyn; Andreas Kramer; Ruxandra Pinto
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

6.  Prediction of poor outcome after hypoxic-ischemic brain injury by diffusion-weighted imaging: A systematic review and meta-analysis.

Authors:  Ruili Wei; Chaonan Wang; Fangping He; Lirong Hong; Jie Zhang; Wangxiao Bao; Fangxia Meng; Benyan Luo
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.